• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

门静脉压力梯度和血清白蛋白:与经颈静脉肝内门体分流术治疗失代偿性肝硬化腹水出现相关的简单联合参数。

Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.

机构信息

Department of Infectious Disease, the First Affiliated Hospital of Anhui Medical University, Hefei, China.

Department of Interventional Radiology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.

出版信息

Clin Mol Hepatol. 2019 Jun;25(2):210-217. doi: 10.3350/cmh.2018.0083. Epub 2019 Mar 22.

DOI:10.3350/cmh.2018.0083
PMID:30897897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6589851/
Abstract

BACKGROUND/AIMS: In recent years, greater assessment accuracy after transjugular intrahepatic portosystemic shunt (TIPS) to ascertain prognosis has become important in decompensated cirrhosis due to portal hypertension. The aim of this study was to assess the ratio of the portal pressure gradient (PPG) pre-TIPS (pre-PPG) to albumin (PPA), which influence ascites formation in cirrhotic patients in the 6-months after TIPS placement, and is a metric introduced in our study.

METHODS

This was a retrospective cohort study of 58 patients with decompensated cirrhosis admitted to an academic hospital for the purpose of TIPS placement. We collected the following data: demographics, laboratory measures, and PPG during the TIPS procedure. Then we analyzed the association between the above data and ascites formation postTIPS in cirrhosis patients.

RESULTS

Twenty-two patients with ascites and 28 without ascites were evaluated. Univariate and binary logistic regression analysis were adjusted for the following variables: to determine prognosis; Child-Pugh scores, lymphocyte count, platelet count, hemoglobin level, albumin level and pre-PPG or PPA. The outcome showed that PPA was better than pre-PPG and albumin for predicting ascites according to area under receiver operating characteristic curves and a statistical model that also showed PPA's influence 6-months post-TIPS.

CONCLUSION

The combined measurement of pre-PPG and albumin, defined as PPA, may provide a better way to predict post-TIPS ascites in decompensated cirrhosis, which underlines the need for a large clinical trial in the future.

摘要

背景/目的:近年来,由于门静脉高压导致的代偿期肝硬化,在经颈静脉肝内门体分流术(TIPS)后进行更准确的评估以确定预后变得尤为重要。本研究的目的是评估 TIPS 前(pre-PPG)门静脉压力梯度(PPG)与白蛋白(PPA)的比值,该比值影响 TIPS 放置后 6 个月内肝硬化患者腹水的形成,这是我们研究中引入的一个指标。

方法

这是一项回顾性队列研究,纳入了 58 例因 TIPS 植入术而入住学术医院的失代偿期肝硬化患者。我们收集了以下数据:人口统计学资料、实验室指标和 TIPS 过程中的 PPG。然后,我们分析了上述数据与肝硬化患者 TIPS 后腹水形成之间的关系。

结果

我们评估了 22 例有腹水和 28 例无腹水的患者。单变量和二元逻辑回归分析调整了以下变量:以确定预后;Child-Pugh 评分、淋巴细胞计数、血小板计数、血红蛋白水平、白蛋白水平和 pre-PPG 或 PPA。结果显示,根据受试者工作特征曲线下面积和统计模型,PPA 比 pre-PPG 和白蛋白更能预测腹水,该模型还显示 PPA 在 TIPS 后 6 个月的影响。

结论

pre-PPG 和白蛋白的联合测量,定义为 PPA,可能为预测失代偿期肝硬化 TIPS 后腹水提供一种更好的方法,这突显了未来进行大型临床试验的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23c2/6589851/4927ff5695ee/cmh-2018-0083f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23c2/6589851/4927ff5695ee/cmh-2018-0083f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23c2/6589851/4927ff5695ee/cmh-2018-0083f1.jpg

相似文献

1
Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.门静脉压力梯度和血清白蛋白:与经颈静脉肝内门体分流术治疗失代偿性肝硬化腹水出现相关的简单联合参数。
Clin Mol Hepatol. 2019 Jun;25(2):210-217. doi: 10.3350/cmh.2018.0083. Epub 2019 Mar 22.
2
Portal decompression by transjugular intrahepatic portosystemic shunt and changes in serum-ascites albumin gradient.经颈静脉肝内门体分流术进行门脉减压及血清腹水白蛋白梯度的变化
J Clin Gastroenterol. 1998 Sep;27(2):149-51. doi: 10.1097/00004836-199809000-00010.
3
Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension.经颈静脉肝内门体分流术治疗门静脉高压症后门静脉压力梯度测量的时机影响。
Gastroenterology. 2017 May;152(6):1358-1365. doi: 10.1053/j.gastro.2017.01.011. Epub 2017 Jan 24.
4
Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.基于贝叶斯网络的门静脉高压症经颈静脉肝内门体分流术后患者生存预测模型
World J Gastroenterol. 2024 Apr 7;30(13):1859-1870. doi: 10.3748/wjg.v30.i13.1859.
5
Right atrial pressure may impact early survival of patients undergoing transjugular intrahepatic portosystemic shunt creation.右心房压力可能会影响接受经颈静脉肝内门体分流术患者的早期生存率。
Ann Hepatol. 2014 Jul-Aug;13(4):411-9.
6
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.经颈静脉肝内门体分流术后,门静脉肝压梯度的靶向降低可改善腹水控制。
Hepatology. 2023 Feb 1;77(2):466-475. doi: 10.1002/hep.32676. Epub 2022 Aug 12.
7
Use of a transjugular intrahepatic portosystemic shunt combined with autologous bone marrow cell infusion in patients with decompensated liver cirrhosis: an exploratory study.经颈静脉肝内门体分流术联合自体骨髓细胞输注在失代偿期肝硬化患者中的应用:一项探索性研究。
Cytotherapy. 2014 Nov;16(11):1575-1583. doi: 10.1016/j.jcyt.2014.04.007.
8
[Preliminary application of transjugular intrahepatic portosystemic shunt in individualized treatment of patients with cirrhotic portal hypertension complicated with refractory ascites and variceal hemorrhage].经颈静脉肝内门体分流术在肝硬化门静脉高压症合并顽固性腹水及曲张静脉出血患者个体化治疗中的初步应用
Zhonghua Yi Xue Za Zhi. 2019 Dec 17;99(47):3737-3740. doi: 10.3760/cma.j.issn.0376-2491.2019.47.012.
9
Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.经颈静脉肝内门体分流术治疗顽固性腹水:单中心经验
Scand J Gastroenterol. 2012 Dec;47(12):1494-500. doi: 10.3109/00365521.2012.703239. Epub 2012 Sep 10.
10
CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.CXCL9 是接受经颈静脉肝内门体分流术治疗的肝硬化患者的预后标志物。
J Hepatol. 2015 Feb;62(2):332-9. doi: 10.1016/j.jhep.2014.09.032. Epub 2014 Oct 17.

引用本文的文献

1
Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis.失代偿期肝硬化住院患者新发失代偿事件的危险因素及其预后影响。
BMC Gastroenterol. 2024 Nov 14;24(1):408. doi: 10.1186/s12876-024-03494-3.
2
Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications.经颈静脉肝内门体分流术时降低门体系统梯度可获得良好的效果,并减少并发症。
World J Gastroenterol. 2023 Apr 21;29(15):2336-2348. doi: 10.3748/wjg.v29.i15.2336.
3
Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis.

本文引用的文献

1
Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.将我们目前对腹水管理的认识转化为针对肝硬化和液体潴留患者的新疗法。
Dig Dis. 2017;35(4):402-410. doi: 10.1159/000456595. Epub 2017 May 3.
2
Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.经颈静脉肝内门体分流术联合覆膜支架增加肝硬化并复发性腹水患者的无移植生存率。
Gastroenterology. 2017 Jan;152(1):157-163. doi: 10.1053/j.gastro.2016.09.016. Epub 2016 Sep 20.
3
Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt.
肝硬化合并门静脉血栓患者的直接口服抗凝剂治疗。
Clin Mol Hepatol. 2021 Oct;27(4):535-552. doi: 10.3350/cmh.2021.0109. Epub 2021 Jun 16.
4
The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?瞬时弹性成像评估门静脉高压症的截断值是否应根据病因不同而有所差异?
Clin Mol Hepatol. 2021 Jan;27(1):91-93. doi: 10.3350/cmh.2020.0311. Epub 2020 Dec 3.
经颈静脉肝内门体分流术联合食管胃静脉曲张栓塞术治疗巨大胃肾分流
World J Hepatol. 2016 Jul 18;8(20):850-7. doi: 10.4254/wjh.v8.i20.850.
4
MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt.终末期肝病患者行经颈静脉肝内门体分流术后,MELD-Na作为30天和90天死亡率的预后指标。
Eur J Gastroenterol Hepatol. 2015 Oct;27(10):1226-7. doi: 10.1097/MEG.0000000000000412.
5
Long-Term Patency and Clinical Analysis of Expanded Polytetrafluoroethylene-Covered Transjugular Intrahepatic Portosystemic Shunt Stent Grafts.膨体聚四氟乙烯覆膜经颈静脉肝内门体分流术支架移植物的长期通畅性及临床分析
J Vasc Interv Radiol. 2015 Sep;26(9):1257-65; quiz 1265. doi: 10.1016/j.jvir.2015.04.005. Epub 2015 May 16.
6
A Standardized Assessment of Functional Disability Predicts 1-year Mortality in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites.功能残疾的标准化评估可预测因顽固性腹水接受经颈静脉肝内门体分流术患者的1年死亡率。
J Clin Gastroenterol. 2016 Jan;50(1):75-9. doi: 10.1097/MCG.0000000000000339.
7
Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.经颈静脉肝内门体分流术治疗肝硬化难治性腹水患者的长期临床结局
J Gastroenterol Hepatol. 2015 Feb;30(2):389-95. doi: 10.1111/jgh.12725.
8
Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis.血清白蛋白的转录后变化:住院肝硬化患者的临床和预后意义。
Hepatology. 2014 Dec;60(6):1851-60. doi: 10.1002/hep.27322. Epub 2014 Nov 3.
9
Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis.预防性使用经颈静脉肝内门体分流术有助于治疗难治性腹水:荟萃回归和试验序贯荟萃分析。
J Clin Gastroenterol. 2014 Mar;48(3):290-9. doi: 10.1097/MCG.0b013e3182a115e9.
10
Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.不同肝病评分系统预测经颈静脉肝内门体分流术创建后早期死亡率的预后能力。
J Vasc Interv Radiol. 2013 Mar;24(3):411-20, 420.e1-4; quiz 421. doi: 10.1016/j.jvir.2012.10.026. Epub 2013 Jan 9.